Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Mallinckrodt
Farmers Insurance
Cerilliant
Deloitte
Teva
Novartis
Federal Trade Commission
Argus Health
Julphar

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204623

« Back to Dashboard
NDA 204623 describes PENNSAID, which is a drug marketed by Horizon Pharma and Nuvo Pharms Inc and is included in two NDAs. It is available from two suppliers. There are nineteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the PENNSAID profile page.

The generic ingredient in PENNSAID is diclofenac sodium. There are forty-seven drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.

Summary for NDA: 204623

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:19
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Dermatological Agents
Ophthalmic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 204623

Suppliers and Packaging for NDA: 204623

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PENNSAID
diclofenac sodium
SOLUTION;TOPICAL 204623 NDA Horizon Pharma Inc. 75987-040 75987-040-05 112 g in 1 BOTTLE, PUMP (75987-040-05)
PENNSAID
diclofenac sodium
SOLUTION;TOPICAL 204623 NDA Horizon Pharma Inc. 75987-040 75987-040-74 2 g in 1 POUCH (75987-040-74)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;TOPICALStrength2%
Approval Date:Jan 16, 2014TE:ATRLD:Yes
Patent:► SubscribePatent Expiration:Oct 17, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Aug 9, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
Patent:► SubscribePatent Expiration:Jul 10, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
UBS
Covington
Accenture
Novartis
Boehringer Ingelheim
Cantor Fitzgerald
Dow
Johnson and Johnson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot